Trial Profile
Allogeneic Transplantation after a Conditioning with Thiotepa, Busulfan and Fludarabin for the treatment of refractory/early relapsed aggressive B-cell non Hodgkin lymphomas: a Phase II Multi-Center Trial
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 16 Sep 2013
Price :
$35
*
At a glance
- Drugs Busulfan (Primary) ; Fludarabine (Primary) ; Thiotepa (Primary) ; Allogeneic stem cell therapy
- Indications Non-Hodgkin's lymphoma
- Focus Therapeutic Use
- 16 Sep 2013 New trial record